Apr 15 2020
The research group led by Contract Assistant Professor Itaru Ninomiya, and Associate Professor Masato Kanazawa of Department of Neurology, Brain Research Institute, Niigata University, has demonstrated for the first time that the levels of an inflammatory protein, pentraxin 3 (PTX3), are elevated during the hyperacute phase of branch atheromatous disease (BAD)—an ischemic stroke subtype—and have the potential as a diagnostic biomarker. BAD, often associated with serious sequalae, presents early symptoms that are similar to lacunar infarction (LI), therefore is extremely difficult to differentiate. Moreover, unlike LI, exacerbation of BAD commonly occurs despite treatment initiation, and early differentiation of BAD might significantly contribute to the development of treatment strategies.
Further details of the discovery of this novel diagnostic marker for ischemic stroke, associated with difficulty in differential diagnosis, were published on April 6, 2020 (Japan time), in the European Journal of Neurology.
Title: Elevated serum pentraxin 3 levels might predict the diagnosis of branch atheromatous disease at a very early stage
Journal: European Journal of Neurology
Authors: Itaru Ninomiya, Masato Kanazawa, Masahiro Uemura, Osamu Onodera
DOI: 10.1111/ene.14249
A Gene Locus Controlling Zinc Content in Common Beans Identified: Nutritional Improvement Expected Through The Molecular Breeding Of Zinc-Enrichmed Varieties
Elevated cdc42 activity is a key initiation event leading to proteinuria. -Regulation of cdc42 activity could be a promising therapy for nephrotic syndrome.-
Temozolomide and radiation treatment lead to dramatic tumor shrinkage and improvement of hearing in an adult brainstem glioma patient with a rare IDH2 mutation